Cinnamic preparations for therapeutic uses



-Patented June 1, 1937 v zios sai PEUTIC USES 'CINNAMIO PREPARATIONS FOB f iacobJacobsom-Paris, France NoDrawing ggplication November 23, 1935,

rial No. 5

I 5 Claims. The invention relates to therapeutic, preparations adapted for intramuscular or subcutaneous injections and containing benzyl cinnamic ester. The object of the invention is to effect improvethe use of this the action of the benzyl ester of cinnamic acid has beneficial effects in connection with the treatment of a variety of diseased conditions of the humanbody has been siderable investigation and study and many publications bearing on the, subject are extant. Among such publications may be mentioned the following:

Comptes Rendue Soc. de Dermatologie of I February 9, 1922.-'Articles by Darier and Jean-.

selme and Jacobson;

Bulletin et Mm. de la Soc. md. des HQpJ, Reports of the Sessions of October 23, 1925, March 25, 1927, and April 19, 19 29; La Presse Mdicale, of March 13,

a by Gosset, Gutmann and Iahel; Paris Mdical, of qctober 25, 1930.--Article by 2 LVy-Solal, et a1.

Publication by Socit dOphtalmologie de Paris of February 1931; Articleby Chevallereau 8: 88891; La Tunisie Mdicale, April, 1932.--Report of the Commission de Tunisie. i a 30 Revenue Internationale du Trachomes, of January, 1932, and April, 1933, by Jean-Sedan. l

Archives de Mdecine et de Pharmacie Mili-q taires of February, 1933.-Article "by Barrel (8:

sm-mine Luc. rtevu r ntemationaie du Traohome of April,

1933- cle by Junes.

Bulletin of the'A cademy of Medicine.'-Report of the Session of July 18, 1933, Volume 110, No. 28 40 on Regression des kratites, etc." I According to published information on the-subject, the preparation employed is ordinarily. a solution or what is known in French as "ether benzyl cinnamique in olive oil in the proportion of 3.2 parts in one volume. In the French 45 hundred parts by a modern English chemical terminology word ether" in the combination represented by the- English word ester. The benzylic ester of cinnamic acid is, however, a. substance which is very difllcuitly soluble in olive oil.

50 I found that better results are obtainableif the percentage of 3.2 of the benzylic ester of cinnamic acid is reduced and in part replaced, within the approximate totality of 3.2 parts, by other ingredients, provided such other ments in products of the stated character with. reference to the physiological effects produced bytype of material. The fact that made the subject of constated would be ingredients are of such character as to contribute one or both of benzyl alcohol and cinnamic acid radicals. For example, if in-the non-oil parts ofthe product there are present in the following relation the following substances, (about 20 grams) benzyl alcohol (about 10-15 cc.) and ethyl cinnamic ester (about 2 co.) the 1111511 mate effect in the human body will apparently be a decomposition of the benzyl cinnamic ester into the,

to wit. benzyl cinnamic ester 5 benzyl alcohol and cinnamicacid,althoughmean- 10 not derived from the cinnamic ester, and cinnamic acid resulting from the presence in the composition of the ethyl cinnamic ester. position alsogre'atly facilitate the-production of a suspension or solution in olive oil inasmuch as a properly prepared solution of the benzyl cinnamic ester in benzyl alcohol, under avoidance of The components of the new com- 15 fusion of the benzyl cinnamic ester in an environ- 20 ment other than benzyl alcohol with the addition of the ethyl cinnamic ester, all in the approximate proportions stated, can be readily incorporated in pure refined olive oil. In the oil suspension the stated mixture of non-oil components preferably constitute about 3.2 parts in one hundred.

Dosages of the preparation are then filled in ampules and sterilized. The ordinary dosefor a normal patient is 1 cc., while for a less healthy patient a dose of V2 cc. is ordinarily used. The dose for children is ordinarily /4 cc. The preferred administration of the product is by way of intramuscular or subcutaneous-injection. The efl'ect is in itself particularly" with respect to micro-orsanisms such as those of tetanus and diphtheria, though the preparationvis not to be regarded as a speciijlc for these organisms. The fields of use and the type of diseased with which their use geous is that which is tions hereinabove referred to.

I claim:

1. A sterilized preparatiorf'constituted of an olive oil suspension of a mixture containing benzyl cinnamic ester and benzyl alcoholin the approximate relation of 20 grams of the former in 15 cc. of the latter and with a total of suspended material approxiis particularly advantain claim 1 in which the non-oily componen -elude ethyl cinnamic indicated by the publicaharmless and even anti-toxic,

conditions in connection ampule-contained therapeutic lation of of 1 cc. for cinnamic ester.

3. The method of preparing a therapeutic preparation which comprises establishing a solution of benzyl cinnamlc ester in henzyl alcohol in the general relation of 20 grams of the former-in about 15cc. of the latter and then incorporating the said solution with olive oil in the approximate proportion of 3.2 of the solution in 100 parts of the product, introducing dosages of the product into. ampules and sterilizing.

4. The method or preparing a therapeutic preparation which comprises establishing a solution of benzyl cinnamic ester in benzyl alcohol in a general relation of 20 grams of the former in about 15 cc. of the latter, adding a cinnamic ester each gram of the benz yl other than the benzyl to said solution in the approximate proportion of of 1 cc. of said ester per gramot the benzyl cinnamic ester, introduclng dosages of the sterilizing.

5. The method of preparing a therapeutic preparation which comprises establishing a solution of benzyl cinnamic, ester in benzyl alcohol product into ampules and in a general relation of 20 grams'oi the former in of the latter, adding ethyl cinnamic. solution in the approidmate propor- JAGOE JACOBSON. 

